Clinical Trial Update: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating low-dose rivaroxaban for cardiovascular disease in patients with advanced chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: The George Institute | Conditions: Chronic Kidney Diseases, Dialysis-dependent Kidney Failure | Phase 3 | Status: COMPLETED